8th Antigen-Specific Immune Tolerance Drug Development Summit
R&D
Building on 7 years of success, the 8th Antigen-Specific Immune Tolerance Summit is back - the only conference dedicated to advancing curative therapies for autoimmune diseases through antigen-specific approaches for tolerance induction.
Agenda highlights include:
- Standardizing the definition and biomarkers of tolerance to inform clinical endpoints for specific disease studies and work towards measurable milestones of efficacy
- Delving into antigen selection for complex autoimmune diseases with multiple antigen drivers to expand the wheelhouse of diseases immune tolerizing strategies can target including celiac disease, Type 1 diabetes, multiple sclerosis, rheumatoid arthritis, IBD, and more
- Advancing durable and efficacious ASIT therapeutics through early-stage clinical trials and beyond
With new companies, new antigens, and new disease targets, you can’t miss this opportunity to capitalize on the wealth of opportunities in antigen-specific immune tolerance drug development and contribute to the transformation of autoimmune disease treatment.
